0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

INFLUENTIAL PUBLICATIONS   |    
Bibliography: Psychopharmacology: Evidence and Treatments
FOCUS 2014;12:184-186. doi:10.1176/appi.focus.12.2.184

Extract

M Bauer,M Adli,R Ricken,E Severus,M Pilhatsch.. Psychopharmacology: evidence and treatments. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs2014; [Epub ahead of print]ST Bird,V Crentsil,R Temple,S Pinheiro,D Demczar,M Stone.: Cardiac safety concerns remain for citalopram at dosages above 40 mg/day. Am J Psychiatry2014; 171:17–19
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2013.13070905]] | [PubMed]L Citrome,TA Ketter,J Cucchiaro,A Loebel.: Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord2014; 155:20–27
[CrossRef][[XSLOpenURL/10.1016/j.jad.2013.10.040]] | [PubMed]S Köhler,S Gaus,T Bschor.. The challenge of treatment in bipolar depression: evidence from clinical guidelines, treatment recommendations and complex treatment situations. Pharmacopsychiatry2014 Feb 18. [Epub ahead of print]A Loebel,J Cucchiaro,R Silva,H Kroger,J Hsu,K Sarma,G Sachs.: Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry2014; 171:160–168
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2013.13070984]] | [PubMed]A Loebel,J Cucchiaro,R Silva,H Kroger,K Sarma,J Xu,JR Calabrese.: Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry2014; 171:169–177
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2013.13070985]] | [PubMed]RS McIntyre,MJ Filteau,L Martin,S Patry,A Carvalho,DS Cha,M Barakat,M Miguelez.: Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord2014; 156:1–7
[CrossRef][[XSLOpenURL/10.1016/j.jad.2013.10.043]] | [PubMed]M Naughton,G Clarke,OF O’Leary,JF Cryan,TG Dinan.: A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord2014; 156:24–35
[CrossRef][[XSLOpenURL/10.1016/j.jad.2013.11.014]] | [PubMed]AF Schatzberg.. A word to the wise about ketamine. Am J Psychiatry2014; 171:262‒264
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2014.13101434]] | [PubMed]MH Trivedi,TL Greer.: Cognitive dysfunction in unipolar depression: implications for treatment. J Affect Disord2014; 152-154:19–27
[CrossRef][[XSLOpenURL/10.1016/j.jad.2013.09.012]] | [PubMed]Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonard B, Nutt DJ, Stephens DN, Wilson S: Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol2013; 27:967–971
[CrossRef][[XSLOpenURL/10.1177/0269881113503509]] | [PubMed]RA de Kleine,BO Rothbaum,A van Minnen.: Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review. Eur J Psychotraumatol2013; 4Geddes JR, Miklowitz DJ: Treatment of bipolar disorder. Lancet2013; 381:1672–1682
[CrossRef][[XSLOpenURL/10.1016/S0140-6736(13)60857-0]] | [PubMed]G Griebel,A Holmes.: 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov2013; 12:667–687
[CrossRef][[XSLOpenURL/10.1038/nrd4075]] | [PubMed]U Heresco-Levy,G Gelfin,B Bloch,R Levin,S Edelman,DC Javitt,I Kremer.: A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol2013; 16:501–506
[CrossRef][[XSLOpenURL/10.1017/S1461145712000910]] | [PubMed]T Kishimoto,V Agarwal,T Kishi,S Leucht,JM Kane,CU Correll.: Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry2013; 18:53–66
[CrossRef][[XSLOpenURL/10.1038/mp.2011.143]] | [PubMed]Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet2013; 382:951–962
[CrossRef][[XSLOpenURL/10.1016/S0140-6736(13)60733-3]] | [PubMed]P McGorry,M Alvarez-Jimenez,E Killackey.: Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry2013; 70:898–900
[CrossRef][[XSLOpenURL/10.1001/jamapsychiatry.2013.264]] | [PubMed]JW Murrough,DV Iosifescu,LC Chang,RK Al Jurdi,CE Green,AM Perez,S Iqbal,S Pillemer,A Foulkes,A Shah,DS Charney,SJ Mathew.: Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry2013; 170:1134–1142
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2013.13030392]] | [PubMed]I Pacchiarotti,DJ Bond,RJ Baldessarini,WA Nolen,H Grunze,RW Licht,RM Post,M Berk,GM Goodwin,GS Sachs,L Tondo,RL Findling,EA Youngstrom,M Tohen,J Undurraga,A González-Pinto,JF Goldberg,A Yildiz,LL Altshuler,JR Calabrese,PB Mitchell,ME Thase,A Koukopoulos,F Colom,MA Frye,GS Malhi,KN Fountoulakis,G Vázquez,RH Perlis,TA Ketter,F Cassidy,H Akiskal,JM Azorin,M Valentí,DH Mazzei,B Lafer,T Kato,L Mazzarini,A Martínez-Aran,G Parker,D Souery,A Ozerdem,SL McElroy,P Girardi,M Bauer,LN Yatham,CA Zarate,AA Nierenberg,B Birmaher,S Kanba,RS El-Mallakh,A Serretti,Z Rihmer,AH Young,GD Kotzalidis,GM MacQueen,CL Bowden,SN Ghaemi,C Lopez-Jaramillo,J Rybakowski,K Ha,G Perugi,S Kasper,JD Amsterdam,RM Hirschfeld,F Kapczinski,E Vieta.: The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry2013; 170:1249–1262
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2013.13020185]] | [PubMed]TL Rodebaugh,EJ Lenze.: Lessons learned from D-cycloserine: the promise and limits of drug facilitation of exposure therapy. J Clin Psychiatry2013; 74:415–416
[CrossRef][[XSLOpenURL/10.4088/JCP.13ac08464]] | [PubMed]Rush AJ: Ketamine for treatment-resistant depression: ready or not for clinical use?Am J Psychiatry2013; 170:1079–1081
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2013.13081034]] | [PubMed]JA Smits,SG Hofmann,D Rosenfield,LB DeBoer,PT Costa,NM Simon,C O’Cleirigh,AE Meuret,L Marques,MW Otto,MH Pollack.: D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. J Consult Clin Psychol2013; 81:1100–1112
[CrossRef][[XSLOpenURL/10.1037/a0034120]] | [PubMed]R Uher.; GENDEP Investigators; MARS Investigators; STAR*D Investigators: Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry2013; 170:207–217
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2012.12020237]] | [PubMed]L Wunderink,RM Nieboer,D Wiersma,S Sytema,FJ Nienhuis.: Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry2013; 70:913–920
[CrossRef][[XSLOpenURL/10.1001/jamapsychiatry.2013.19]] | [PubMed]A Young,J Calabrese,U Gustafsson,M Berk,S McElroy,M Thase,T Suppes,W Earley.: Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. Int J Bipolar Disord2013; 1:10
[CrossRef][[XSLOpenURL/10.1186/2194-7511-1-10]]M Bauer,P Ritter,H Grunze,A Pfennig.. Treatment options for acute depression in bipolar disorder. Bipolar Disord2012; 14:37‒50
[CrossRef][[XSLOpenURL/10.1111/bdi.2012.14.issue-s2]] | [PubMed]Kupfer DJ, Frank E, Phillips ML: Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet2012; 379:1045–1055
[CrossRef][[XSLOpenURL/10.1016/S0140-6736(11)60602-8]] | [PubMed]M De Hert,J Detraux,R van Winkel,W Yu,CU Correll.: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol2012; 8:114–126
[CrossRef][[XSLOpenURL/10.1038/nrendo.2011.156]]S Miyamoto,N Miyake,LF Jarskog,WW Fleischhacker,JA Lieberman.: Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry2012; 17:1206–1227
[CrossRef][[XSLOpenURL/10.1038/mp.2012.47]] | [PubMed]H Mohler.. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology2012; 62: 42‒53
[CrossRef][[XSLOpenURL/10.1016/j.neuropharm.2011.08.040]] | [PubMed]GI Papakostas,RC Shelton,JM Zajecka,B Etemad,K Rickels,A Clain,L Baer,ED Dalton,GR Sacco,D Schoenfeld,M Pencina,A Meisner,T Bottiglieri,E Nelson,D Mischoulon,JE Alpert,JG Barbee,S Zisook,M Fava.: L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry2012; 169:1267–1274
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2012.11071114]] | [PubMed]AC Swann,B Lafer,G Perugi,MA Frye,M Bauer,WM Bahk,J Scott,K Ha,T Suppes.: Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry2013; 170:31–42
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2012.12030301]] | [PubMed]S Banerjee,J Hellier,M Dewey,R Romeo,C Ballard,R Baldwin,P Bentham,C Fox,C Holmes,C Katona,M Knapp,C Lawton,J Lindesay,G Livingston,N McCrae,E Moniz-Cook,J Murray,S Nurock,M Orrell,J O’Brien,M Poppe,A Thomas,R Walwyn,K Wilson,A Burns.: Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet2011; 378:403–411
[CrossRef][[XSLOpenURL/10.1016/S0140-6736(11)60830-1]] | [PubMed]A Cipriani,C Barbui,G Salanti,J Rendell,R Brown,S Stockton,M Purgato,LM Spineli,GM Goodwin,JR Geddes.: Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet2011; 378:1306–1315
[CrossRef][[XSLOpenURL/10.1016/S0140-6736(11)60873-8]] | [PubMed]RD Dobkin,M Menza,KL Bienfait,M Gara,H Marin,MH Mark,A Dicke,J Friedman.. Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management source. Am J Geriatr Psychiatry2011;19: 222‒229
[CrossRef][[XSLOpenURL/10.1097/JGP.0b013e3181e448f7]] | [PubMed]AJ Rush,MH Trivedi,JW Stewart,AA Nierenberg,M Fava,BT Kurian,D Warden,DW Morris,JF Luther,MM Husain,IA Cook,RC Shelton,IM Lesser,SG Kornstein,SR Wisniewski.: Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry2011; 168:689–701
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2011.10111645]] | [PubMed]D Taylor,N Meader,V Bird,S Pilling,F Creed,D Goldberg.: Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy. Br J P Psychiatry2011; 198:179–188
[CrossRef][[XSLOpenURL/10.1192/bjp.bp.110.077610]]E Vieta,F Colom.. Therapeutic options in treatment-resistant depression. Ann Med2011; 43:512‒530
[CrossRef][[XSLOpenURL/10.3109/07853890.2011.583675]] | [PubMed]A Yildiz,E Vieta,S Leucht,RJ Baldessarini.: Efficacy of antimanic treatments: meta- analysis of randomized, controlled trials. Neuropsychopharmacology2011; 36:375–389
[CrossRef][[XSLOpenURL/10.1038/npp.2010.192]] | [PubMed]Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ: International consensus study of antipsychotic dosing. Am J Psychiatry2010; 167:686–693
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2009.09060802]] | [PubMed]PE Holtzheimer.: Advances in the management of treatment-resistant depression. Focus2010; 8:488–500JM Kane,CU Correll.: Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry2010; 71:1115–1124
[CrossRef][[XSLOpenURL/10.4088/JCP.10r06264yel]] | [PubMed]JH Krystal,SJ Mathew,DC D’Souza,A Garakani,H Gunduz-Bruce,DS Charney.: Potential psychiatric applications of metabotropic glutamate receptor glutamate receptor agonists and antagonists. CNS Drugs2010; 24:669–693
[CrossRef][[XSLOpenURL/10.2165/11533230-000000000-00000]] | [PubMed]JF Goldberg,RH Perlis,CL Bowden,ME Thase,DJ Miklowitz,LB Marangell,JR Calabrese,AA Nierenberg,GS Sachs.: Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry2009; 166:173–181
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2008.08050746]] | [PubMed]JC Nelson,GI Papakostas.: Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry2009; 166:980–991
[CrossRef][[XSLOpenURL/10.1176/appi.ajp.2009.09030312]] | [PubMed]AJ Guastella,R Richardson,PF Lovibond,RM Rapee,JE Gaston,P Mitchell,MR Dadds.: A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry2008; 63:544–549
[CrossRef][[XSLOpenURL/10.1016/j.biopsych.2007.11.011]] | [PubMed]HA Nasrallah.: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry2008; 13:27–35
[CrossRef][[XSLOpenURL/10.1038/sj.mp.4002066]] | [PubMed]M Mula,S Pini,GB Cassano.: The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol2007; 27:263–272
[CrossRef][[XSLOpenURL/10.1097/jcp.0b013e318059361a]] | [PubMed]

Figures in this Article

First Page Preview

View Large
First page PDF preview
Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

+

References

Bauer  M;  Adli  M;  Ricken  R;  Severus  E;  Pilhatsch  M.  Psychopharmacology: evidence and treatments. Role of lithium augmentation in the management of major depressive disorder.  CNS Drugs 2014; [Epub ahead of print]
 
Bird  ST;  Crentsil  V;  Temple  R;  Pinheiro  S;  Demczar  D;  Stone  M:  Cardiac safety concerns remain for citalopram at dosages above 40 mg/day.  Am J Psychiatry 2014; 171:17–19
[CrossRef] | [PubMed]
 
Citrome  L;  Ketter  TA;  Cucchiaro  J;  Loebel  A:  Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.  J Affect Disord 2014; 155:20–27
[CrossRef] | [PubMed]
 
Köhler  S;  Gaus  S;  Bschor  T.  The challenge of treatment in bipolar depression: evidence from clinical guidelines, treatment recommendations and complex treatment situations.  Pharmacopsychiatry 2014 Feb 18. [Epub ahead of print]
 
Loebel  A;  Cucchiaro  J;  Silva  R;  Kroger  H;  Hsu  J;  Sarma  K;  Sachs  G:  Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.  Am J Psychiatry 2014; 171:160–168
[CrossRef] | [PubMed]
 
Loebel  A;  Cucchiaro  J;  Silva  R;  Kroger  H;  Sarma  K;  Xu  J;  Calabrese  JR:  Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.  Am J Psychiatry 2014; 171:169–177
[CrossRef] | [PubMed]
 
McIntyre  RS;  Filteau  MJ;  Martin  L;  Patry  S;  Carvalho  A;  Cha  DS;  Barakat  M;  Miguelez  M:  Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach.  J Affect Disord 2014; 156:1–7
[CrossRef] | [PubMed]
 
Naughton  M;  Clarke  G;  O’Leary  OF;  Cryan  JF;  Dinan  TG:  A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.  J Affect Disord 2014; 156:24–35
[CrossRef] | [PubMed]
 
Schatzberg  AF.  A word to the wise about ketamine.  Am J Psychiatry 2014; 171:262‒264
[CrossRef] | [PubMed]
 
Trivedi  MH;  Greer  TL:  Cognitive dysfunction in unipolar depression: implications for treatment.  J Affect Disord 2014; 152-154:19–27
[CrossRef] | [PubMed]
 
Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonard B, Nutt DJ, Stephens DN, Wilson S: Benzodiazepines: risks and benefits. A reconsideration.  J Psychopharmacol 2013; 27:967–971
[CrossRef] | [PubMed]
 
de Kleine  RA;  Rothbaum  BO;  van Minnen  A:  Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review.  Eur J Psychotraumatol 2013; 4
 
Geddes JR, Miklowitz DJ: Treatment of bipolar disorder.  Lancet 2013; 381:1672–1682
[CrossRef] | [PubMed]
 
Griebel  G;  Holmes  A:  50 years of hurdles and hope in anxiolytic drug discovery.  Nat Rev Drug Discov 2013; 12:667–687
[CrossRef] | [PubMed]
 
Heresco-Levy  U;  Gelfin  G;  Bloch  B;  Levin  R;  Edelman  S;  Javitt  DC;  Kremer  I:  A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.  Int J Neuropsychopharmacol 2013; 16:501–506
[CrossRef] | [PubMed]
 
Kishimoto  T;  Agarwal  V;  Kishi  T;  Leucht  S;  Kane  JM;  Correll  CU:  Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.  Mol Psychiatry 2013; 18:53–66
[CrossRef] | [PubMed]
 
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.  Lancet 2013; 382:951–962
[CrossRef] | [PubMed]
 
McGorry  P;  Alvarez-Jimenez  M;  Killackey  E:  Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more.  JAMA Psychiatry 2013; 70:898–900
[CrossRef] | [PubMed]
 
Murrough  JW;  Iosifescu  DV;  Chang  LC;  Al Jurdi  RK;  Green  CE;  Perez  AM;  Iqbal  S;  Pillemer  S;  Foulkes  A;  Shah  A;  Charney  DS;  Mathew  SJ:  Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.  Am J Psychiatry 2013; 170:1134–1142
[CrossRef] | [PubMed]
 
Pacchiarotti  I;  Bond  DJ;  Baldessarini  RJ;  Nolen  WA;  Grunze  H;  Licht  RW;  Post  RM;  Berk  M;  Goodwin  GM;  Sachs  GS;  Tondo  L;  Findling  RL;  Youngstrom  EA;  Tohen  M;  Undurraga  J;  González-Pinto  A;  Goldberg  JF;  Yildiz  A;  Altshuler  LL;  Calabrese  JR;  Mitchell  PB;  Thase  ME;  Koukopoulos  A;  Colom  F;  Frye  MA;  Malhi  GS;  Fountoulakis  KN;  Vázquez  G;  Perlis  RH;  Ketter  TA;  Cassidy  F;  Akiskal  H;  Azorin  JM;  Valentí  M;  Mazzei  DH;  Lafer  B;  Kato  T;  Mazzarini  L;  Martínez-Aran  A;  Parker  G;  Souery  D;  Ozerdem  A;  McElroy  SL;  Girardi  P;  Bauer  M;  Yatham  LN;  Zarate  CA;  Nierenberg  AA;  Birmaher  B;  Kanba  S;  El-Mallakh  RS;  Serretti  A;  Rihmer  Z;  Young  AH;  Kotzalidis  GD;  MacQueen  GM;  Bowden  CL;  Ghaemi  SN;  Lopez-Jaramillo  C;  Rybakowski  J;  Ha  K;  Perugi  G;  Kasper  S;  Amsterdam  JD;  Hirschfeld  RM;  Kapczinski  F;  Vieta  E:  The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.  Am J Psychiatry 2013; 170:1249–1262
[CrossRef] | [PubMed]
 
Rodebaugh  TL;  Lenze  EJ:  Lessons learned from D-cycloserine: the promise and limits of drug facilitation of exposure therapy.  J Clin Psychiatry 2013; 74:415–416
[CrossRef] | [PubMed]
 
Rush AJ: Ketamine for treatment-resistant depression: ready or not for clinical use? Am J Psychiatry 2013; 170:1079–1081
[CrossRef] | [PubMed]
 
Smits  JA;  Hofmann  SG;  Rosenfield  D;  DeBoer  LB;  Costa  PT;  Simon  NM;  O’Cleirigh  C;  Meuret  AE;  Marques  L;  Otto  MW;  Pollack  MH:  D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables.  J Consult Clin Psychol 2013; 81:1100–1112
[CrossRef] | [PubMed]
 
Uher  R; GENDEP Investigators; MARS Investigators; STAR*D Investigators:  Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.  Am J Psychiatry 2013; 170:207–217
[CrossRef] | [PubMed]
 
Wunderink  L;  Nieboer  RM;  Wiersma  D;  Sytema  S;  Nienhuis  FJ:  Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.  JAMA Psychiatry 2013; 70:913–920
[CrossRef] | [PubMed]
 
Young  A;  Calabrese  J;  Gustafsson  U;  Berk  M;  McElroy  S;  Thase  M;  Suppes  T;  Earley  W:  Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies.  Int J Bipolar Disord 2013; 1:10
[CrossRef]
 
Bauer  M;  Ritter  P;  Grunze  H;  Pfennig  A.  Treatment options for acute depression in bipolar disorder.  Bipolar Disord 2012; 14:37‒50
[CrossRef] | [PubMed]
 
Kupfer DJ, Frank E, Phillips ML: Major depressive disorder: new clinical, neurobiological, and treatment perspectives.  Lancet 2012; 379:1045–1055
[CrossRef] | [PubMed]
 
De Hert  M;  Detraux  J;  van Winkel  R;  Yu  W;  Correll  CU:  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.  Nat Rev Endocrinol 2012; 8:114–126
[CrossRef]
 
Miyamoto  S;  Miyake  N;  Jarskog  LF;  Fleischhacker  WW;  Lieberman  JA:  Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.  Mol Psychiatry 2012; 17:1206–1227
[CrossRef] | [PubMed]
 
Mohler  H.  The GABA system in anxiety and depression and its therapeutic potential.  Neuropharmacology 2012; 62: 42‒53
[CrossRef] | [PubMed]
 
Papakostas  GI;  Shelton  RC;  Zajecka  JM;  Etemad  B;  Rickels  K;  Clain  A;  Baer  L;  Dalton  ED;  Sacco  GR;  Schoenfeld  D;  Pencina  M;  Meisner  A;  Bottiglieri  T;  Nelson  E;  Mischoulon  D;  Alpert  JE;  Barbee  JG;  Zisook  S;  Fava  M:  L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.  Am J Psychiatry 2012; 169:1267–1274
[CrossRef] | [PubMed]
 
Swann  AC;  Lafer  B;  Perugi  G;  Frye  MA;  Bauer  M;  Bahk  WM;  Scott  J;  Ha  K;  Suppes  T:  Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis.  Am J Psychiatry 2013; 170:31–42
[CrossRef] | [PubMed]
 
Banerjee  S;  Hellier  J;  Dewey  M;  Romeo  R;  Ballard  C;  Baldwin  R;  Bentham  P;  Fox  C;  Holmes  C;  Katona  C;  Knapp  M;  Lawton  C;  Lindesay  J;  Livingston  G;  McCrae  N;  Moniz-Cook  E;  Murray  J;  Nurock  S;  Orrell  M;  O’Brien  J;  Poppe  M;  Thomas  A;  Walwyn  R;  Wilson  K;  Burns  A:  Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.  Lancet 2011; 378:403–411
[CrossRef] | [PubMed]
 
Cipriani  A;  Barbui  C;  Salanti  G;  Rendell  J;  Brown  R;  Stockton  S;  Purgato  M;  Spineli  LM;  Goodwin  GM;  Geddes  JR:  Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.  Lancet 2011; 378:1306–1315
[CrossRef] | [PubMed]
 
Dobkin  RD;  Menza  M;  Bienfait  KL;  Gara  M;  Marin  H;  Mark  MH;  Dicke  A;  Friedman  J.  Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management source.  Am J Geriatr Psychiatry 2011;19: 222‒229
[CrossRef] | [PubMed]
 
Rush  AJ;  Trivedi  MH;  Stewart  JW;  Nierenberg  AA;  Fava  M;  Kurian  BT;  Warden  D;  Morris  DW;  Luther  JF;  Husain  MM;  Cook  IA;  Shelton  RC;  Lesser  IM;  Kornstein  SG;  Wisniewski  SR:  Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.  Am J Psychiatry 2011; 168:689–701
[CrossRef] | [PubMed]
 
Taylor  D;  Meader  N;  Bird  V;  Pilling  S;  Creed  F;  Goldberg  D:  Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy.  Br J P Psychiatry 2011; 198:179–188
[CrossRef]
 
Vieta  E;  Colom  F.  Therapeutic options in treatment-resistant depression.  Ann Med 2011; 43:512‒530
[CrossRef] | [PubMed]
 
Yildiz  A;  Vieta  E;  Leucht  S;  Baldessarini  RJ:  Efficacy of antimanic treatments: meta- analysis of randomized, controlled trials.  Neuropsychopharmacology 2011; 36:375–389
[CrossRef] | [PubMed]
 
Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ: International consensus study of antipsychotic dosing.  Am J Psychiatry 2010; 167:686–693
[CrossRef] | [PubMed]
 
Holtzheimer  PE:  Advances in the management of treatment-resistant depression.  Focus 2010; 8:488–500
 
Kane  JM;  Correll  CU:  Past and present progress in the pharmacologic treatment of schizophrenia.  J Clin Psychiatry 2010; 71:1115–1124
[CrossRef] | [PubMed]
 
Krystal  JH;  Mathew  SJ;  D’Souza  DC;  Garakani  A;  Gunduz-Bruce  H;  Charney  DS:  Potential psychiatric applications of metabotropic glutamate receptor glutamate receptor agonists and antagonists.  CNS Drugs 2010; 24:669–693
[CrossRef] | [PubMed]
 
Goldberg  JF;  Perlis  RH;  Bowden  CL;  Thase  ME;  Miklowitz  DJ;  Marangell  LB;  Calabrese  JR;  Nierenberg  AA;  Sachs  GS:  Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD.  Am J Psychiatry 2009; 166:173–181
[CrossRef] | [PubMed]
 
Nelson  JC;  Papakostas  GI:  Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.  Am J Psychiatry 2009; 166:980–991
[CrossRef] | [PubMed]
 
Guastella  AJ;  Richardson  R;  Lovibond  PF;  Rapee  RM;  Gaston  JE;  Mitchell  P;  Dadds  MR:  A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder.  Biol Psychiatry 2008; 63:544–549
[CrossRef] | [PubMed]
 
Nasrallah  HA:  Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.  Mol Psychiatry 2008; 13:27–35
[CrossRef] | [PubMed]
 
Mula  M;  Pini  S;  Cassano  GB:  The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence.  J Clin Psychopharmacol 2007; 27:263–272
[CrossRef] | [PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 26.  >
Psychiatric News
PubMed Articles